Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10577094	
Filing Date		2006-04-26	
First Named Inventor Dietro		ar KRAUTWURST	
Art Unit			
Examiner Name			
Attorney Docket Number		102790-211/30246US	

					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E)ate	Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where ges or Relev	
	1										
If you wisl	h to a	i dd additional U.S. Patei	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant Re		Releva		Lines where ges or Relev	
	1										
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	d button	Add		
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	or ,	vhere Rel	or Relevant	T6
	1										С
If you wis	h to a	l Id additional Foreign P	atent Do	cument	citation	information pl	I lease click the Add	button	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Cite No	Include name of the a (book, magazine, jour publisher, city and/or	nal, seri	al, symp	osium,	catalog, etc), o					Τs

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10577094
Filing Date		2006-04-26
First Named Inventor Dietm		ar KRAUTWURST
Art Unit		
Examiner Name		
		100700 0110001010

1	coronal offactory epithelium since. Neuroreport. 14, 1123-7.	
2	Sanchez-Montanes M.A. and Pearce T.C. (2002) Why do offsclory neurons have unspecified receptive fields? Biosystems, 67, 229-38.	
3	Sato T., Hirono J., Tonoke M. and Takebayashi M. (1994) Tuning specificities to aliphatic odorants in mouse oldsclory receptor neurons and their local distribution. J. Neurophysiol, 72, 2990-0.	
4	Scott J.W. and Brierley T. (1999) A functional map in rat offactory epithelium. Chem Senses, 24, 675-90.	
5	Seamon K.B. and Daly J.W. (1986) Forskolin: its biological and chemical properties. Adv Cyclic Nucleotide protein Phosphorylation Res, 20, 1-150.	
6	Sicard G. and Holley A. (1984) Receptor cell responses to odorants: similarities and differences among odorants. Brain Res, 292, 283-96.	
7	Smit M.J. and lyengar R. (1998) Mammalian adenylyl cyclases. Adv Second Messenger Phosphoprotein Res, 32, 1-21.	
8	Thastrup O., Davson A.P., Scharff O., Foder B., Cullen P.J., Drobak B.K., Bjernum P.J., Christensen S.B. and Hanley M.R. (1994) Thips.pargin. a novel molecular probe for studying intracellular calcium release and storage.	
9	Touhara K. (2002) Odor discrimination by G protein-coupled olfactory receptors. Microsac Res Tech, 58, 135-41.	
10	Touhara K., Sengoku S., Inaki K., Tsuboi A., Hirono J., Salo T., Sakano H. and Haga T. (1999) Functional identification and reconstitution of an odorant receptor in single offactory neurons. Proc Natl Acad Sci USA, 96, 4040-5	
11	Welzel C.H., Oles M., Welterdieck C., Kuczkowiak M., Gisselmann G. and Hatt H. (1999) Specificity and sensitivity of a human olidacty reception flandscraigly expressioned in human embryonic lidiney 293 ceris and Xenopus Laevis oxyles. J. Neutroc 19, 7426-33.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10577094
Filing Date		2006-04-26
First Named Inventor Dietro		ar KRAUTWURST
Art Unit		
Examiner Name		
Attorney Docket Number		102790-211/30246US

	12		g S.T., Trinh K., Hacker B., Chan G.C., Lowe G., Gaggar A., Xia Z. type III adenylyl cyclase gene leads to peripheral and behavioral 17.				
	13	Youn 1153	g J.M. and Trask B.J. (2002) The sense of smell: Genomics of veri 60.	tebrate odorant recept	lors. Hum Mol Genet, 11,		
	14		H., Ivic L., Otaki J.M., Hasimoto M., Mikoshiba K. and Forestein S malian odorant receptor. Science, 279, 237-42.	. (1998) Functional e	expression of a		
	15		lya S., Echevern F. and Nguyen J. (2001) The human olfactory re EARCH0018.	ceptor repertoire. Ge	nome Biol, 2,		
	16	Englis	sh language Preliminary Report on Patentability dated July 27, 200	06 for application PCT	/EP2004/012086		
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add						
	EXAMINER SIGNATURE						
Examine	r Signa	ature		Date Considered			

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3), 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10577094		
Filing Date		2006-04-26		
First Named Inventor Dietro		nar KRAUTWURST		
Art Unit				
Examiner Name				
Attorney Docket Number		102790-211/30246US		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):	
---	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 177(vi).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- __ □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torm or the signature.							
	Signature	/Andrew N. Parfomak/	Date (YYYY-MM-DD)	2006-10-17			
	Name/Print	Andrew N. Parfomak	Registration Number	32431			

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.